{"id":"https://openalex.org/W1945923482","doi":"https://doi.org/10.1111/j.1360-0443.2011.03577.x","title":"A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin\u2010dependent individuals","display_name":"A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin\u2010dependent individuals","publication_year":2011,"publication_date":"2011-07-12","ids":{"openalex":"https://openalex.org/W1945923482","doi":"https://doi.org/10.1111/j.1360-0443.2011.03577.x","mag":"1945923482","pmid":"https://pubmed.ncbi.nlm.nih.gov/21749526"},"language":"en","primary_location":{"id":"doi:10.1111/j.1360-0443.2011.03577.x","doi":"https://doi.org/10.1111/j.1360-0443.2011.03577.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1360-0443.2011.03577.x","pdf_url":null,"source":{"id":"https://openalex.org/S70513841","display_name":"Addiction","issn_l":"0965-2140","issn":["0965-2140","1360-0443"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Addiction","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080366556","display_name":"Leslie Amass","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Leslie Amass","raw_affiliation_strings":["Schering Corporation, A Division of Merck and Company, Kenilworth, NJ 07830, USA. la@biopsych.com","Schering Corporation, A Division of Merck and Company, Kenilworth, NJ, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Schering Corporation, A Division of Merck and Company, Kenilworth, NJ 07830, USA. la@biopsych.com","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Schering Corporation, A Division of Merck and Company, Kenilworth, NJ, USA,","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015774766","display_name":"Vilma Pukeleviciene","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vilma Pukeleviciene","raw_affiliation_strings":["Kaunas District Center for Addictive Disorders, Kaunas, Lithuania,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kaunas District Center for Addictive Disorders, Kaunas, Lithuania,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025109748","display_name":"Emilis Subata","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emilis Subata","raw_affiliation_strings":["Vilnius Centre for Addictive Disorders, Vilnius, Lithuania,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vilnius Centre for Addictive Disorders, Vilnius, Lithuania,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111511243","display_name":"Ant\u00f3nio Rocha Almeida","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ant\u00f3nio Rocha Almeida","raw_affiliation_strings":["Centro de Atendimento a Toxicodependentes de Aveiro, Aveiro, Portugal,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Atendimento a Toxicodependentes de Aveiro, Aveiro, Portugal,","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Maria Chiara Pieri","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maria Chiara Pieri","raw_affiliation_strings":["SerT Polo Est, Bologna, Italy,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SerT Polo Est, Bologna, Italy,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083388626","display_name":"Pietro Fausto D\u2019Egidio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210147037","display_name":"Azienda USL di Pescara","ror":"https://ror.org/048ym4d69","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210147037"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Pietro D'Egidio","raw_affiliation_strings":["ASL-Ser.T., Pescara, Italy,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ASL-Ser.T., Pescara, Italy,","institution_ids":["https://openalex.org/I4210147037"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006004730","display_name":"Zdenka Stankova","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zdenka Stankova","raw_affiliation_strings":["Private practice, Labem, Czech Republic,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Private practice, Labem, Czech Republic,","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ant\u00f3nio Costa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ant\u00f3nio Costa","raw_affiliation_strings":["Unidade de Desabituac\u0327a\u0303o\u2014Centro das Taipas, Lisboa, Portugal,","Unidade de Desabitua\u00e7\u00e3o\u2014Centro das Taipas, Lisboa, Portugal,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Unidade de Desabituac\u0327a\u0303o\u2014Centro das Taipas, Lisboa, Portugal,","institution_ids":[]},{"raw_affiliation_string":"Unidade de Desabitua\u00e7\u00e3o\u2014Centro das Taipas, Lisboa, Portugal,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012730650","display_name":"Bobby P. Smyth","orcid":"https://orcid.org/0000-0003-3797-5541","observed_orcids":["https://orcid.org/0000-0003-3797-5541"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bobby P. Smyth","raw_affiliation_strings":["Drug Treatment Centre Board, Dublin 2, Ireland,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Treatment Centre Board, Dublin 2, Ireland,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060582996","display_name":"Slavko Sakoman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210123681","display_name":"Sisters of Charity Hospital","ror":"https://ror.org/024a8dx81","country_code":"HR","type":"healthcare","lineage":["https://openalex.org/I4210123681"]}],"countries":["HR"],"is_corresponding":false,"raw_author_name":"Slavko Sakoman","raw_affiliation_strings":["Clinical Hospital \u2018Sestre milosrdnice\u2019, Zagreb, Croatia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Hospital \u2018Sestre milosrdnice\u2019, Zagreb, Croatia","institution_ids":["https://openalex.org/I4210123681"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yan Wei","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yan Wei","raw_affiliation_strings":["Schering Corporation, A Division of Merck and Company, Kenilworth, NJ, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Schering Corporation, A Division of Merck and Company, Kenilworth, NJ, USA,","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060812676","display_name":"John Strang","orcid":"https://orcid.org/0000-0002-5413-2725","observed_orcids":["https://orcid.org/0000-0002-5413-2725"]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"John Strang","raw_affiliation_strings":["Institute of Psychiatry, Kings College London, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Psychiatry, Kings College London, London, UK","institution_ids":["https://openalex.org/I183935753"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5080366556"],"corresponding_institution_ids":["https://openalex.org/I1285764155"],"apc_list":{"value":4600,"currency":"USD","value_usd":4600},"apc_paid":null,"fwci":2.5093,"has_fulltext":false,"cited_by_count":27,"citation_normalized_percentile":{"value":0.87641521,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"107","issue":"1","first_page":"142","last_page":"151"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11199","display_name":"Pain Management and Opioid Use","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2703","display_name":"Anesthesiology and Pain Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/buprenorphine-naloxone","display_name":"buprenorphine/naloxone","score":0.9789999723434448},{"id":"https://openalex.org/keywords/heroin-dependence","display_name":"heroin addiction","score":0.7310000061988831},{"id":"https://openalex.org/keywords/opioid-use-disorder","display_name":"opioid use disorder","score":0.8999999761581421},{"id":"https://openalex.org/keywords/opioid-maintenance-treatment","display_name":"opioid maintenance treatment","score":0.7110000252723694},{"id":"https://openalex.org/keywords/treatment-retention","display_name":"treatment retention","score":0.718999981880188},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.8610000014305115},{"id":"https://openalex.org/keywords/illicit-opioid-use","display_name":"illicit opioid use","score":0.7649999856948853},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.4970000088214874},{"id":"https://openalex.org/keywords/patient-acceptability","display_name":"patient acceptability","score":0.5759999752044678}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8701879382133484},{"id":"https://openalex.org/C2778949969","wikidata":"https://www.wikidata.org/wiki/Q407721","display_name":"Buprenorphine","level":4,"score":0.7903332710266113},{"id":"https://openalex.org/C2778750930","wikidata":"https://www.wikidata.org/wiki/Q4540629","display_name":"(+)-Naloxone","level":4,"score":0.6335067749023438},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.5497251152992249},{"id":"https://openalex.org/C2778903686","wikidata":"https://www.wikidata.org/wiki/Q60168","display_name":"Heroin","level":3,"score":0.5470231771469116},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5467109680175781},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.5270395874977112},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5239167809486389},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.4959803521633148},{"id":"https://openalex.org/C2779418921","wikidata":"https://www.wikidata.org/wiki/Q1639178","display_name":"Opioid use disorder","level":4,"score":0.45773980021476746},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2789815664291382},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.13580915331840515},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.13492801785469055},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000286","descriptor_name":"Administration, Sublingual","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002047","descriptor_name":"Buprenorphine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002047","descriptor_name":"Buprenorphine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002047","descriptor_name":"Buprenorphine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005060","descriptor_name":"Europe","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006556","descriptor_name":"Heroin Dependence","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009270","descriptor_name":"Naloxone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009270","descriptor_name":"Naloxone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009270","descriptor_name":"Naloxone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010349","descriptor_name":"Patient Compliance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013375","descriptor_name":"Substance Withdrawal Syndrome","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015819","descriptor_name":"Substance Abuse, Intravenous","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057194","descriptor_name":"Intention to Treat Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060046","descriptor_name":"Maintenance Chemotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060828","descriptor_name":"Induction Chemotherapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1111/j.1360-0443.2011.03577.x","doi":"https://doi.org/10.1111/j.1360-0443.2011.03577.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1360-0443.2011.03577.x","pdf_url":null,"source":{"id":"https://openalex.org/S70513841","display_name":"Addiction","issn_l":"0965-2140","issn":["0965-2140","1360-0443"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Addiction","raw_type":"journal-article"},{"id":"pmid:21749526","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21749526","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Addiction (Abingdon, England)","raw_type":"Clinical Trial, Phase IV"},{"id":"pmh:oai:kclpure.kcl.ac.uk:publications/e9d242b8-bb56-4076-9a6c-521af29afc2e","doi":null,"is_oa":false,"landing_page_url":"https://kclpure.kcl.ac.uk/portal/en/publications/e9d242b8-bb56-4076-9a6c-521af29afc2e","pdf_url":null,"source":{"id":"https://openalex.org/S4306400216","display_name":"Research Portal (King's College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I183935753","host_organization_name":"King's College London","host_organization_lineage":["https://openalex.org/I183935753"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Amass, L, Pukeleviciene, V, Subata, E, Almeida, A R, Pieri, M C, D'Egidio, P, Stankova, Z, Costa, A, Smyth, B P, Sakoman, S, Wei, Y & Strang, J 2012, 'A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals', Addiction, vol. 107, no. 1, pp. 142 - 151. https://doi.org/10.1111/j.1360-0443.2011.03577.x","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":45,"referenced_works":["https://openalex.org/W125827253","https://openalex.org/W383399767","https://openalex.org/W568696044","https://openalex.org/W1902909473","https://openalex.org/W1923689435","https://openalex.org/W1975806001","https://openalex.org/W1977681341","https://openalex.org/W1978946510","https://openalex.org/W1980315117","https://openalex.org/W2006556752","https://openalex.org/W2017627129","https://openalex.org/W2027873427","https://openalex.org/W2044839076","https://openalex.org/W2050443628","https://openalex.org/W2057252503","https://openalex.org/W2061007797","https://openalex.org/W2065431063","https://openalex.org/W2071956502","https://openalex.org/W2074706074","https://openalex.org/W2078154157","https://openalex.org/W2078504997","https://openalex.org/W2090989559","https://openalex.org/W2096264877","https://openalex.org/W2096868511","https://openalex.org/W2097910464","https://openalex.org/W2099536555","https://openalex.org/W2100833669","https://openalex.org/W2108978934","https://openalex.org/W2121153184","https://openalex.org/W2121538801","https://openalex.org/W2121647917","https://openalex.org/W2133039181","https://openalex.org/W2135214206","https://openalex.org/W2141882410","https://openalex.org/W2144736441","https://openalex.org/W2145139215","https://openalex.org/W2147528480","https://openalex.org/W2148488822","https://openalex.org/W2151493975","https://openalex.org/W2152591738","https://openalex.org/W2152947180","https://openalex.org/W2169255825","https://openalex.org/W2171498933","https://openalex.org/W2586322456","https://openalex.org/W2992603718"],"related_works":["https://openalex.org/W2414192172","https://openalex.org/W4414300365","https://openalex.org/W1976869578","https://openalex.org/W2168594794","https://openalex.org/W2078154157","https://openalex.org/W2007802571","https://openalex.org/W4410355607","https://openalex.org/W2014053202","https://openalex.org/W4417158716","https://openalex.org/W2091692004"],"abstract_inverted_index":{"AIMS:":[0],"To":[1],"provide":[2],"controlled":[3],"data":[4],"on":[5,93,146],"direct":[6,79,238],"induction":[7,31,83,122,140,222,240,248],"with":[8,40,181,253],"buprenorphine/naloxone":[9,221,239,257],"(BNX)":[10],"versus":[11,120,128,211,215],"indirect":[12,81,129,246],"buprenorphine":[13],"(BPN)-to-BNX":[14],"induction.":[15],"DESIGN:":[16],"Phase":[17],"4,":[18],"prospective,":[19],"randomized,":[20],"active-drug":[21],"controlled,":[22],"parallel-group":[23],"trial":[24],"consisting":[25],"of":[26,37,58,67,75,85,143,153,174,232,255],"a":[27,224],"2-day,":[28],"double-blind,":[29],"double-dummy":[30],"phase":[32],"followed":[33],"by":[34],"26":[35],"days":[36],"open-label":[38],"treatment":[39,106,156,231],"BNX.":[41],"SETTING:":[42],"Nineteen":[43],"sites":[44],"in":[45,164,184],"10":[46],"European":[47],"countries":[48],"from":[49],"March":[50],"2008":[51],"to":[52,78,118,236,242,245],"December":[53],"2009.":[54],"PARTICIPANTS:":[55],"A":[56],"total":[57],"187":[59],"opioid-dependent":[60],"men":[61],"and":[62,80,108,113,151,188,195,201,226,249],"women":[63],"\u2265":[64],"15":[65],"years":[66],"age.":[68],"MEASUREMENTS:":[69],"The":[70],"primary":[71],"objective":[72],"was":[73,123,149,179,223,250],"assessment":[74],"patient":[76],"response":[77,117],"BNX":[82,91,171],"[proportion":[84],"patients":[86,154],"receiving":[87],"the":[88],"scheduled":[89],"16-mg":[90],"dose":[92,139,173],"day":[94,98,147],"3":[95],"(i.e.":[96],"first":[97],"post-induction)].":[99],"Secondary":[100],"assessments":[101],"included":[102],"illicit":[103,185],"drug":[104],"use,":[105],"retention":[107,196],"compliance,":[109],"withdrawal":[110],"scale":[111],"scores,":[112],"safety.":[114],"FINDINGS:":[115],"Patient":[116],"direct-":[119,214],"indirect-BNX":[121],"similar":[124,199,244],"[direct":[125],"91.4%":[126],"(85/93)":[127],"90.4%":[130],"(85/94);":[131],"95%":[132],"confidence":[133],"interval":[134],"(CI):":[135],"-7.3%,":[136],"9.2%].":[137],"Rapid":[138],"(16":[141],"mg":[142,176],"BPN":[144],"equivalent":[145],"2)":[148],"acceptable":[150],"72%":[152],"completed":[155],"(day":[157],"28).":[158],"There":[159],"were":[160,198,208],"no":[161,189],"significant":[162],"differences":[163],"secondary":[165],"measures":[166],"across":[167,177],"groups.":[168],"An":[169],"average":[170],"maintenance":[172,230],"15.3":[175],"groups":[178],"associated":[180,252],"substantial":[182],"reductions":[183],"opioid":[186,233],"use":[187],"self-reported":[190],"intravenous":[191,256],"misuse.":[192,258],"Treatment":[193],"compliance":[194],"rates":[197,207],"(98.5%":[200],"81.3%,":[202],"respectively).":[203],"Treatment-emergent":[204],"adverse":[205],"event":[206],"comparable:":[209],"75%":[210],"74%":[212],"for":[213,229],"indirect-induction":[216],"groups,":[217],"respectively.":[218],"CONCLUSIONS:":[219],"Direct":[220],"safe":[225],"effective":[227],"strategy":[228],"dependence.":[234],"Response":[235],"high-dose":[237],"appears":[241],"be":[243],"buprenorphine-to-buprenorphine/naloxone":[247],"not":[251],"reports":[254]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}